De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 12

Peer-Review Report of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Dec 27, 2021; 13(12): 1991-2004
Published online Dec 27, 2021. doi: 10.4254/wjh.v13.i12.1991

Table 1 Summary management strategies

Lifestyle modifications	Dietary modification
	Exercise/ physical activity
	Avoid heavy alcohol consumption
	Benefit with coffee consumption
Pharmacotherapy	No approved drug for MAFLD in post liver transplants patients
Bariatric treatment	Surgery
Bariatric treatment	Endoscopic
Tailored Immunosuppression	Early taper of steroids
	Decreasing CNIs as possible
	Avoid/cautious use of mTOR inhibitors

CNIs: Calcineurin inhibitors; MAFLD: Metabolic dysfunction-associated fatty liver disease.

Citation: Han MAT, Olivo R, Choi CJ, Pyrsopoulos N. De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation. World J Hepatol 2021; 13(12): 1991-2004
URL: https://www.wjgnet.com/1948-5182/full/v13/i12/1991.htm
DOI: https://dx.doi.org/10.4254/wjh.v13.i12.1991

Han MAT, Olivo R, Choi CJ, Pyrsopoulos N. De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation. World J Hepatol 2021; 13(12): 1991-2004 [PMID: 35070003 DOI: 10.4254/wjh.v13.i12.1991]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.